Stroke risk stratification in a "real-world" elderly anticoagulated atrial fibrillation population

Journal of Cardiovascular Electrophysiology

Volumn 22, Issue 1, 2011, Pages 25-30

  Poli, Daniela ^a   Lip, Gregory Yh ^b   Antonucci, Emilia ^a   Grifoni, Elisa ^a   Lane, Deirdre ^b  

^a CAREGGI UNIVERSITY HOSPITAL   (Italy)

^b UNIVERSITY OF BIRMINGHAM   (United Kingdom)

Author keywords

anticoagulion; aspirin; atrial fibrillation; elderly; stroke

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; ANTITHROMBOCYTIC AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR;

AGED; ANTICOAGULANT THERAPY; ARTICLE; FEMALE; HEART ATRIUM FIBRILLATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MORBIDITY; PRIORITY JOURNAL; STROKE; THROMBOEMBOLISM; TRANSIENT ISCHEMIC ATTACK;

AGED; ANTICOAGULANTS; ATRIAL FIBRILLATION; COMORBIDITY; FEMALE; HUMANS; INCIDENCE; ITALY; MALE; RISK ASSESSMENT; RISK FACTORS; STROKE;

EID: 78751543538     PISSN: 10453873     EISSN: 15408167     Source Type: Journal    
DOI: 10.1111/j.1540-8167.2010.01858.x     Document Type: Article

References (23)

1. Stroke Risk in Atrial Fibrillation Working Group: Independent predictors of stroke in patients with atrial fibrillation: A systematic review. Neurology 2007; 69: 546-554.
2. Hughes M, Lip GY,: Guideline Development Group, National Clinical Guideline for Management of Atrial Fibrillation in Primary and Secondary Care, National Institute for Health and Clinical Excellence. Stroke and thromboembolism in atrial fibrillation: A systematic review of stroke risk factors, risk stratification schema and cost effectiveness data. Thromb Haemost 2008; 99: 295-304.
3. Wang TJ, Massaro JM, Levy D, Vasan RS, Wolf PA, D'Agostino RB, Larson MG, Kannel WB, Benjamin EJ,: A risk score for predicting stroke or death in individuals with new-onset atrial fibrillation in the community: The Framingham Heart Study. JAMA 2003; 290: 1049-1056.
4. Atrial Fibrillation Investigators: Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation. Analysis of pooled data from five randomized controlled trials. Arch Intern Med 1994; 154: 1449-1457.
5. Lip GY, Nieuwlaat R, Pisters R, Lane DA, Crijns HJ,: Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: The euro heart survey on atrial fibrillation. Chest 2010; 137: 263-272.
6. Fuster V, Rydén LE, Cannom DS, Crijns HJ, Curtis AB, Ellenbogen KA, Halperin JL, Le Heuzey JY, Kay GN, Lowe JE, Olsson SB, Prystowsky EN, Tamargo JL, Wann S, Smith SC Jr, Jacobs AK, Adams CD, Anderson JL, Antman EM, Halperin JL, Hunt SA, Nishimura R, Ornato JP, Page RL, Riegel B, Priori SG, Blanc JJ, Budaj A, Camm AJ, Dean V, Deckers JW, Despres C, Dickstein K, Lekakis J, McGregor K, Metra M, Morais J, Osterspey A, Tamargo JL, Zamorano JL,: American College of Cardiology/American Heart Association Task Force on Practice Guidelines; European Society of Cardiology Committee for Practice Guidelines; European Heart Rhythm Association; Heart Rhythm Society. ACC/AHA/ESC 2006 Guidelines for the Management of Patients with Atrial Fibrillation: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation): Developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. Circulation 2006; 114: e257-e354.
7. National Collaborating Centre for Chronic Conditions: Atrial Fibrillation: National Clinical Guideline for Management in Primary and Secondary Care. London: Royal College of Physicians, 2006.
8. Singer DE, Albers GW, Dalen JE, Fang MC, Go AS, Halperin JL, Lip GY, Manning WJ,: American College of Chest Physicians. Antithrombotic therapy in atrial fibrillation: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008; 133: 546S-592S.
9. Connolly SJ, Eikelboom J, O'Donnell M, Pogue J, Yusuf S,: Challenges of establishing new antithrombotic therapies in atrial fibrillation. Circulation 2007; 116: 449-455.
10. Hylek EM, Frison L, Henault LE, Cupples A,: Disparate stroke rates on warfarin among contemporaneous cohorts with atrial fibrillation: Potential insights into risk from a comparative analysis of SPORTIF III versus SPORTIF V. Stroke. 2008; 39: 3009-3014.
11. Gorin L, Fauchier L, Nonin E, de Labriolle A, Haguenoer K, Cosnay P, Babuty D, Charbonnier B,: Antithrombotic treatment and the risk of death and stroke in patients with atrial fibrillation and a CHADS2 score=1. Thromb Haemost 2010; 103: 833-840.
12. Lee BH, Park JS, Park JH, Park JS, Kwak JJ, Hwang ES, Kim SK, Choi DH, Kim YH, Pak HN,: The effect and safety of the anti-thrombotic therapies in patients with atrial fibrillation and CHADS2 score 1. J Cardiovasc Electrophysiol 2010; 21: 501-507.
13. Healey JS, Hart RG, Pogue J, Pfeffer MA, Hohnloser SH, De Caterina R, Flaker G, Yusuf S, Connolly SJ,: Risks and benefits of oral anticoagulation compared with clopidogrel plus aspirin in patients with atrial fibrillation according to stroke risk: The Atrial Fibrillation Clopidogrel Trial with Irbesartan for Prevention of Vascular Events (ACTIVE-W). Stroke 2008; 39: 1482-1486.
14. Lip GYH, Halperin JL,: Improving stroke risk stratification in atrial fibrillation. Am J Med 2010; 123: 483-488.
15. van Walraven C, Hart RG, Wells GA, Petersen P, Koudstaal PJ, Gullov AL, Hellemons BS, Koefed BG, Laupacis A,: A clinical prediction rule to identify patients with atrial fibrillation and a low risk for stroke while taking aspirin. Arch Intern Med 2003; 163: 936-943.
16. Gage BF, Waterman AD, Shannon W, Boechler M, Rich MW, Radford MJ,: Validation of clinical classification schemes for predicting stroke: Results from the National Registry of Atrial Fibrillation. JAMA 2001; 285: 2864-2870.
17. Lip GY,: Anticoagulation therapy and the risk of stroke in patients with atrial fibrillation at 'moderate risk'[CHADS2 score=1]: Simplifying stroke risk assessment and thromboprophylaxis in real-life clinical practice. Thromb Haemost 2010; 103: 683-685.
18. 2 score of 1. J Cardiovasc Electrophysiol 2010; 21: 508-510.
19. Prystowsky EN, Camm J, Lip GY, Allessie M, Bergmann JF, Breithardt G, Brugada J, Crijns H, Ellinor PT, Mark D, Naccarelli G, Packer D, Tamargo J,: The impact of new and emerging clinical data on treatment strategies for atrial fibrillation. J Cardiovasc Electrophysiol 2010 Apr 8. [Epub ahead of print.
20. Karthikeyan G, Eikelboom JW,: The CHADS2 score for stroke risk stratification in atrial fibrillation-friend or foe? Thromb Haemost 2010; 104: 45- 48.
21. Bunch TJ, Crandall BG, Weiss JP, May HT, Bair TL, Osborn JS, Anderson JL, Lappe DL, Muhlestein JB, Nelson J, Allison S, Foley T, Anderson L, Day JD,: Warfarin is not needed in low-risk patients following atrial fibrillation ablation procedures. J Cardiovasc Electrophysiol 2009; 20: 988-993.
22. Baruch L, Gage BF, Horrow J, Juul-Möller S, Labovitz A, Persson M, Zabalgoitia M,: Can patients at elevated risk of stroke treated with anticoagulants be further risk stratified? Stroke 2007; 38: 2459-2463.
23. Poli D, Antonucci E, Grifoni E, Abbate R, Gensini GF, Prisco D,: Stroke risk in atrial fibrillation patients on warfarin. Predictive ability of risk stratification schemes for primary and secondary prevention. Thromb Haemost 2009; 101: 367-372.